Few public health problems are of greater global importance today than antimicrobial resistance. Multidrug resistant pathogens are a challenge in high-income countries, and many countries, including the USA and the UK, have created national plans as well as legislation and regulation to address antibiotic resistance issues. However, middle-income and low-income countries are likely to bear the brunt of this problem. Many of our citizens do not have access to antibiotics. In the Lancet Series on antimicrobial access, sustainability, and effectiveness, Ramanan Laxminarayan and colleagues1 make the case that far younger than 5 years could be averted by universal access to antibiotics.1 Marc Mendelson and colleagues2 echo this finding in their Series paper, and highlight the need for improved access to diagnostics so that infectious diseases can be identified and treated correctly. Even for those with access to first-line antibiotics, more expensive second-line antibiotics are not affordable for our countries. Some new antibiotics are needed, but conserving the antibiotics we already have is the highest immediate priority.


7 Van Boeckel TP, Brower C, Gilbert M, et al. Global trends in antimicrobial use in finding in their Series paper, and highlight the need for access, sustainability, and effectiveness, Ramanan access to antibiotics. In the Lancet the brunt of this problem. Many of our citizens do not have middle-income and low-income countries are likely to bear regulation to address antibiotic resistance issues. However, resistant pathogens are a challenge in high-income importance today than antimicrobial resistance. Multidrug National action for global gains in antimicrobial resistance

8 Zhang QQ, Ying GG, Pan CG, Liu YS, Zhao JL. Comprehensive evaluation of community-acquired pneumonia deaths in children more people die from lack of access to antibiotics than younger than 5 years could be averted by universal access to antibiotics.1 Marc Mendelson and colleagues2 echo this finding in their Series paper, and highlight the need for improved access to diagnostics so that infectious diseases can be identified and treated correctly. Even for those with access to first-line antibiotics, more expensive second-line antibiotics are not affordable for our countries. Some new antibiotics are needed, but conserving the antibiotics we already have is the highest immediate priority.

9 Price LB, Stegger M, Hasman H, et al. Antibiotics are needed, but conserving the antibiotics we already have is the highest immediate priority.

10 Price LB, Stegger M, Hasman H, et al. Antibiotics are needed, but conserving the antibiotics we already have is the highest immediate priority.

11 Price LB, Stegger M, Hasman H, et al. Antibiotics are needed, but conserving the antibiotics we already have is the highest immediate priority.


14 Woolhouse M, Ward M, van Bunnik B, Farrar J. Antimicrobial resistance in Staphylococcus aureus 10 Price LB, Stegger M, Hasman H, et al. Antibiotics are needed, but conserving the antibiotics we already have is the highest immediate priority.


National action for global gains in antimicrobial resistance
The World Health Assembly endorsed the Global Action Plan for Antimicrobial Resistance in May, 2015, calling on member states to put in place national plans within 2 years. The Series papers by Osman Dar and Christine Årdal and their colleagues review the evidence base for national and regional policies on antimicrobial resistance and call for coordinated global action to support the WHO plan. Hospital antibiotic stewardship and infection prevention and control are among the most broadly effective policies in all settings.

However, few low-income and middle-income countries have taken even preliminary steps in this direction. We are ahead of the curve because our countries—India, Mozambique, South Africa, and Kenya—along with four other countries in Africa and Asia (Nepal, Tanzania, Uganda, and Vietnam) have assessed the current status of antibiotic access and resistance and have begun to develop national action plans.

The Government of India’s first step is bringing 24 antibiotics under a new Schedule H1 drug category; sale of these drugs without a doctor’s prescription could attract substantial penalties. Pharmacists now have to document details of patient, drug, and prescriber, subject to regular inspections by drug control officials. Through the Kayakalp and Mission Indradhanush, the Government of India is also working to reduce the burden of bacterial infections by improving access to sanitation and vaccination at an unprecedented scale.

The Indian Council of Medical Research has established a National Programme on Antimicrobial Surveillance, in ten laboratories at academic centres, that covers priority pathogens identified by WHO, and the Drugs Controller General of India has started a pharmacovigilance programme for antibiotics. In addition, the Department of Biotechnology and its Biotechnology Industry Research Assistance Council are investing in science and gathering information on antibiotic use in food animals with the aim of reducing unnecessary use. To improve public health and reduce the bacterial disease burden, Mozambique is among the earliest adopters in sub-Saharan Africa of vaccination against Haemophilus influenzae type b and pneumococcal disease, and has scheduled introduction of rotavirus vaccine.

Meanwhile, in Kenya, the Ministry of Health formed a multisectoral National Antimicrobial Resistance Advisory Committee in 2015 with representatives from human and animal health, and created a position for an antimicrobial resistance focal point. The Ministry is now designing a national plan, with support from the advisory committee. The Ministry also actively supports formal awareness-raising activities throughout the country.

In 2011, the South African Medical Journal published the State of the World’s Antibiotics, 2015. The current national resistance profile was included in CDDEP’s report State of the World’s Antibiotics, 2015. Mozambique is among the earliest adopters in sub-Saharan Africa of vaccination against Haemophilus influenzae type b and pneumococcal disease, and has scheduled introduction of rotavirus vaccine.

In our countries we face many of the same challenges as high-income countries in confronting antimicrobial resistance. But we also face additional challenges: weaker health-care systems, difficulty in enforcing regulations, an inadequate supply of trained health-care providers, poor public health infrastructure, a higher burden of infectious disease, and limited resources.

We commend the Lancet Series and its recommendations for providing a factual basis for developing national plans to reduce the burden of infection, to improve infection prevention and control,
to increase surveillance, and to move towards access to antibiotics for all while preserving the global effectiveness of these life-saving drugs. The strategies must address antibiotic use in hospitals, communities, and agriculture, in partnership with all relevant sectors. Extending access to all must be balanced with the conservation of our current antibiotic supply. While global cooperation is essential, action must come from the national level, with national-level ownership and regional collaboration.

Our first steps show that national-level policy action on antimicrobial resistance is possible in low-income and middle-income countries, and, as highlighted in this Lancet Series, attention to preserving access to effective antibiotics for all is an urgent need.

Nazira Abdula, James Macharia, Aaron Motsoaledi, *Soumya Swaminathan, Krishnaswamy VijayRaghavan

Ministry of Health, Government of Mozambique, Maputo, Mozambique (NA); Ministry of Health, Government of Kenya, Nairobi, Kenya (JM); Department of Health, Pretoria, South Africa (AM); and Departments of Health Research (SS) and Biotechnology (KV), Government of India, New Delhi, India

soumyas@trcchennai.in

NA is Minister of Health for the Government of Mozambique. JM is Cabinet Secretary, Ministry of Health for the Government of Kenya. AM is Minister of Health for the Government of South Africa. SS is Secretary, Department of Health Research and KV is Secretary, Department of Biotechnology for the Government of India. We declare no competing interests.


